Sugi Predict

Sugi Predict / Compounds / SCHEMBL19780067

SCHEMBL19780067

SCHEMBL19780067

COC(=O)c1cc(C(F)(F)F)[nH]n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.59
▸ ALOX15 P16050 1/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ CACNA1I Q9P0X4 1/20 0.42
▸ CFTR P13569 5/20 0.41
▸ MAPT P10636 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ RBP4 P02753 1/20 0.40
▸ PABPC1 P11940 1/20 0.40
▸ CRHBP P24387 1/20 0.40
▸ CRHR2 Q13324 1/20 0.40
▸ DGAT2 Q96PD7 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14524215 0.84 MAPK1 (0.61) MAPK1NPC1POLBRAB9AMEN1
SCHEMBL14955814 0.82 KMT2A (0.49) ALOX15POLBKMT2AL3MBTL1CACNA1I
SCHEMBL31308506 0.80 ALOX15 (0.48) MAPK1ALOX15CACNA1ICFTRRBP4
SCHEMBL7258330 0.79 MAPK1 (0.54) MAPK1NPC1POLBRAB9AMEN1
SCHEMBL7255814 0.79 MAPK1 (0.54) MAPK1NPC1POLBRAB9AMEN1
SCHEMBL2360520 0.78 HCAR2 (0.52) MAPK1ALOX15RBP4NOTUMHPGD
SCHEMBL30345115 0.78 ALOX15 (0.41) MAPK1ALOX15CACNA1ICFTRRBP4
SCHEMBL3053796 0.77 ALOX15 (0.51) MAPK1ALOX15CACNA1ICFTRRBP4
SCHEMBL6757804 0.77 ALOX15 (0.48) MAPK1ALOX15KMT2ACACNA1ICFTR
SCHEMBL17224847 0.76 MAPK1 (0.51) MAPK1NPC1POLBRAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108546-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-23 — — US disclosed
WO-2025264700-A1 GIP RECEPTOR AGONIST COMPOUNDS ELI LILLY AND COMPANY (US) 2025-12-26 — — WO disclosed
WO-2025096660-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2025096653-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2025096657-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2025096654-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2025096662-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2025096658-A1 COMPOSITIONS AND INHIBITORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2023144793-A1 POL THETA INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-08-03 — — WO disclosed
US-20210395221-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS INC (US) 2021-12-23 — — US disclosed
US-10781200-B2 Therapeutic inhibitory compounds ATTUNE PHARMACEUTICALS, INC. (US) 2020-09-22 — — US disclosed
US-10781200-B2 Therapeutic inhibitory compounds ATTUNE PHARMACEUTICALS, INC. (US) 2020-09-22 — — US disclosed
US-20200239435-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2020-07-30 — — US disclosed
US-20200239435-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2020-07-30 — — US disclosed
US-20190292155-A1 THERAPEUTIC INHIBITORY COMPOUNDS LIFESCI PHARMACEUTICALS INC (BB) 2019-09-26 — — US disclosed
US-20190292155-A1 THERAPEUTIC INHIBITORY COMPOUNDS LIFESCI PHARMACEUTICALS INC (BB) 2019-09-26 — — US disclosed
US-10301284-B2 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. (BB) 2019-05-28 — — US disclosed
US-10301284-B2 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. (BB) 2019-05-28 — — US disclosed
US-20180297984-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2018-10-18 — — US disclosed
WO-2018011628-A1 THERAPEUTIC INHIBITORY COMPOUNDS LIFESCI PHARMACEUTICALS, INC. (BB) 2018-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180297984-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 MAPK1 1148/4885ALOX15 269/4885NPC1 959/4885
US-20200239435-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 MAPK1 1148/4885ALOX15 269/4885NPC1 959/4885
US-20210395221-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 MAPK1 1148/4885ALOX15 269/4885NPC1 959/4885
US-10781200-B2 Therapeutic inhibitory compounds KLKB1, SERPINB1, SERPINE1 MAPK1 1148/4885ALOX15 269/4885NPC1 959/4885
US-20260108546-A1 GIP RECEPTOR AGONIST COMPOUNDS GIPR, GLP1R, GCGR MAPK1 2308/4885ALOX15 2453/4885NPC1 638/4885
US-20190292155-A1 THERAPEUTIC INHIBITORY COMPOUNDS CFD, C9, CFH MAPK1 2210/4885ALOX15 190/4885NPC1 938/4885
US-10301284-B2 Therapeutic inhibitory compounds KLKB1, SERPINB1, SERPINE1 MAPK1 1148/4885ALOX15 269/4885NPC1 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.